heart failure with preserved ejection fraction

5 · 20 / page

Ask MedXY AI

Latest news

Tag

CardiologyempagliflozinEMPEROR-Preserved Trial

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Outcomes of Empagliflozin in Heart Failure with Preserved Ejection Fraction

By MedXY|Nov 28, 2025

This review comprehensively summarizes recent studies (2021–2024) from the EMPEROR-Preserved trial, highlighting empagliflozin’s consistent benefits on cardiovascular and renal outcomes, quality of life, and key clinical subgroups in HFpEF

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

Cardiologyheart failure with preserved ejection fractionobesity

heart failure with preserved ejection fraction

Latest news

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Outcomes of Empagliflozin in Heart Failure with Preserved Ejection Fraction

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

Evaluating β-Blocker Use and Health Status in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the TOPCAT Trial

Volenrelaxin in HFpEF: Unexpected Worsening of Congestion Despite Improvements in Left Atrial Function

Semaglutide and Tirzepatide Significantly Reduce Hospitalization and Mortality in Cardiometabolic HFpEF Patients: Real-World Evidence